Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEp SEA: LP352 in Dravet Syndrome
NCT06660394Phase 3Active, not recruiting
- Sponsor
- Longboard Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing LP352 with Placebo (2 arms). Primary endpoint: Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline at 15 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
bexicaserin
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT06660394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660394.